Objetivo Colorectal cancer (CRC) is the most common neoplastic pathology in the developed world. It is the second in frequency in men after prostate cancer and the second in women after breast cancer. Survival at five years, if all stages are taken into account, is approximately 50%. That represents a mortality of 20 cases per 100,000 inhabitants per year. The five-year survival of early stages, a situation almost equivalent to cure, is approximately 90%, whereas in advanced or metastatic stages it is less than 10%. Therefore, early diagnosis plays a central role in the improvement of survival rates. The main goal of this project is to find new ways to detect the cancer in the very early stages. To do so, the sample collection must be as simple, economic and convenient as possible. Only in this manner, regular screening approaching 100% of adult population will take place. The approach we propose is the identification and validation of new biomarkers in urine that can be used to diagnose colorectal cancer (CRC) at a very early stage. The central hypothesis is that CRC associated metabolites in the urine of patients can be segregated from patients with polyps (some of them precursors of CRC) and control subjects, and that their levels are correlated with clinical diagnostics of a CRC stage. Urine is an easy collectible biofluid for its non-invasiveness, and it can provide early detection of cancers. New sample measurement protocols and techniques are enhancing both selectivity and sensitivity by orders of magnitude, such as SPME and Twisters or GC/LC-MS systems (GCxGX/LC-QTOF-MS). The more sensitivity and selectivity, the more confindent diagnosis could be made at earlier stages of the cancerous process leading to a better survivability rate.Moreover, our proposal includes a multi-cohort, multi-laboratory validation of the findings, therefore ensuring that any discovery can readily be applied to any population and instrumentation around de world. Ámbito científico medical and health sciencesclinical medicineoncologyprostate cancersocial sciencessociologydemographymortalitymedical and health sciencesclinical medicineoncologybreast cancermedical and health sciencesclinical medicineoncologycolorectal cancermedical and health sciencesbasic medicinepathology Palabras clave Colorectal cancer metabolomics biomarkers urine volatiles GCxGC-MS LC-MS cohort validation instrumental bias multivariate analysis pattern recognition open source software diagnostics test Programa(s) H2020-EU.1.3. - EXCELLENT SCIENCE - Marie Skłodowska-Curie Actions Main Programme H2020-EU.1.3.2. - Nurturing excellence by means of cross-border and cross-sector mobility Tema(s) MSCA-IF-2017 - Individual Fellowships Convocatoria de propuestas H2020-MSCA-IF-2017 Consulte otros proyectos de esta convocatoria Régimen de financiación MSCA-IF - Marie Skłodowska-Curie Individual Fellowships (IF) Coordinador FUNDACIO INSTITUT D'INVESTIGACIO SANITARIA PERE VIRGILI (IISPV) Aportación neta de la UEn € 257 191,20 Dirección CARRER ESCORXADOR 43003 Tarragona España Ver en el mapa Región Este Cataluña Tarragona Tipo de actividad Research Organisations Enlaces Contactar con la organización Opens in new window Participación en los programas de I+D de la UE Opens in new window Red de colaboración de HORIZON Opens in new window Coste total € 257 191,20 Socios (1) Ordenar alfabéticamente Ordenar por aportación neta de la UE Ampliar todo Contraer todo Socio Las organizaciones asociadas contribuyen a la aplicación de la acción, pero no firman el acuerdo de subvención. THE REGENTS OF THE UNIVERSITY OF CALIFORNIA Estados Unidos Aportación neta de la UEn € 0,00 Dirección FRANKLIN STREET 1111 12 FLOOR 94607 OAKLAND CA Ver en el mapa Tipo de actividad Higher or Secondary Education Establishments Enlaces Contactar con la organización Opens in new window Sitio web Opens in new window Participación en los programas de I+D de la UE Opens in new window Red de colaboración de HORIZON Opens in new window Coste total € 172 130,40